CN112888447A - 减少菌群失调和恢复微生物群系的方法 - Google Patents

减少菌群失调和恢复微生物群系的方法 Download PDF

Info

Publication number
CN112888447A
CN112888447A CN201980068341.3A CN201980068341A CN112888447A CN 112888447 A CN112888447 A CN 112888447A CN 201980068341 A CN201980068341 A CN 201980068341A CN 112888447 A CN112888447 A CN 112888447A
Authority
CN
China
Prior art keywords
pharmaceutical composition
subject
seq
administered
clostridium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980068341.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·诺曼
B·奥莱
B·罗伯茨
R·梅农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedanta Biosciences Inc
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Publication of CN112888447A publication Critical patent/CN112888447A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10—Detection mode being characterised by the assay principle
    • C12Q2565/101—Interaction between at least two labels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980068341.3A 2018-08-17 2019-08-16 减少菌群失调和恢复微生物群系的方法 Pending CN112888447A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862765165P 2018-08-17 2018-08-17
US62/765,165 2018-08-17
US201862724185P 2018-08-29 2018-08-29
US62/724,185 2018-08-29
US201962815395P 2019-03-08 2019-03-08
US62/815,395 2019-03-08
US201962829513P 2019-04-04 2019-04-04
US62/829,513 2019-04-04
US201962829959P 2019-04-05 2019-04-05
US62/829,959 2019-04-05
PCT/US2019/046926 WO2020037271A1 (en) 2018-08-17 2019-08-16 Methods of decreasing dysbiosis and restoring a microbiome

Publications (1)

Publication Number Publication Date
CN112888447A true CN112888447A (zh) 2021-06-01

Family

ID=69525842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980068341.3A Pending CN112888447A (zh) 2018-08-17 2019-08-16 减少菌群失调和恢复微生物群系的方法

Country Status (8)

Country Link
US (2) US12161680B2 (https=)
EP (1) EP3836946B1 (https=)
JP (1) JP7558170B2 (https=)
KR (1) KR20210091119A (https=)
CN (1) CN112888447A (https=)
AU (1) AU2019321681A1 (https=)
IL (2) IL317775A (https=)
WO (1) WO2020037271A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113486954A (zh) * 2021-07-06 2021-10-08 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
CN114496279A (zh) * 2022-01-12 2022-05-13 广州保量医疗科技有限公司 菌群移植配型的排序方法、系统、计算机设备及存储介质
CN119970806A (zh) * 2025-02-25 2025-05-13 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用
CN120779034A (zh) * 2025-07-15 2025-10-14 中山大学附属口腔医院 一种牙周炎相关标志物及应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CN116942833A (zh) 2011-12-01 2023-10-27 国立大学法人 东京大学 诱导调节性t细胞的增殖或积累的人源细菌
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
WO2020037271A1 (en) 2018-08-17 2020-02-20 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
KR102503766B1 (ko) * 2020-06-16 2023-02-23 씨제이바이오사이언스 주식회사 장내 마이크로바이옴 지수를 결정하기 위한 장치, 방법 및 명령을 기록한 기록 매체
CN111796043B (zh) * 2020-08-15 2022-02-22 山东北大高科华泰制药有限公司 注射用盐酸罂粟碱粉针剂及其质量检测方法
WO2022159711A1 (en) 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy
US20240173365A1 (en) * 2021-06-28 2024-05-30 Vedanta Biosciences, Inc. Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease
JP2024540203A (ja) * 2021-11-08 2024-10-31 アルティメット メディシン アーゲー ミクログリア機能障害を治療し、代謝機能障害を改善するための方法および組成物
WO2024218184A1 (en) * 2023-04-20 2024-10-24 Ecole Polytechnique Federale De Lausanne (Epfl) AN ANTIBIOTIC AND A MICROORGANISM HAVING BILE ACID 7α-DEHYDROXYLATION ACTIVITY FOR TREATING NON-INFECTIOUS DISEASES
EP4704871A2 (en) * 2023-04-28 2026-03-11 Vedanta Biosciences, Inc. Compositions and methods for treating clostridioides difficile infection
WO2025076184A1 (en) 2023-10-03 2025-04-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2025093778A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269321A1 (en) * 2005-03-03 2009-10-29 Toshihiro Sashihara Immune Function Modulating Agents
WO2011033310A1 (en) * 2009-09-17 2011-03-24 William John Martin Encapsulated intestinal flora extracted from feces for use in the treatment of gastrointestinal disorders
WO2017218680A1 (en) * 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
WO2018080477A1 (en) * 2016-10-26 2018-05-03 The Joan & Irwin Jacobs Technion-Cornell Institute Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols
US20180169153A1 (en) * 2014-11-25 2018-06-21 Evelo Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft verses host disease
US20180169157A1 (en) * 2016-06-14 2018-06-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180221286A1 (en) * 2013-03-14 2018-08-09 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635496T2 (de) 1995-09-15 2006-07-27 Gerding, Dale N., Chicago Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
EP2337569A4 (en) 2008-09-25 2013-04-03 Univ New York COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING THE STOMACH DARM, SKIN AND NOSE MICROBIOTA
ES2730828T3 (es) * 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
PH12013500224A1 (en) 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012162335A2 (en) 2011-05-23 2012-11-29 Washington State University Research Foundation Use of photosynthetic pigment stabilizing agents to regulate ripening and quality in fruits and vegetables
ES2662793T3 (es) 2011-09-14 2018-04-09 Nubiyota Llc Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos
CN116942833A (zh) 2011-12-01 2023-10-27 国立大学法人 东京大学 诱导调节性t细胞的增殖或积累的人源细菌
IN2014DN07752A (https=) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2013146319A1 (ja) 2012-03-30 2013-10-03 味の素株式会社 糖尿病誘起細菌
EP3686284A1 (en) 2012-05-18 2020-07-29 Genome Research Limited Methods and groups
CN106620189B (zh) 2012-06-06 2021-11-19 上海交通大学 改善肠道菌群结构的方法及应用
CA3212215A1 (en) 2012-11-23 2014-05-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2899925A1 (en) 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
WO2014150094A1 (en) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Butyrogenic bacteria as probiotics to treat clostridium difficile
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
AU2014331610B2 (en) 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6617935B2 (ja) 2014-04-10 2019-12-11 国立研究開発法人理化学研究所 Ｔｈ１７細胞の誘導のための組成物及び方法
WO2015164555A1 (en) 2014-04-23 2015-10-29 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
PT3146065T (pt) 2014-05-19 2025-01-14 Memorial Sloan Kettering Cancer Center Métodos e composições para reduzir a infecção por clostridium difficile
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
CA3254897A1 (en) 2014-11-25 2026-03-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
CA2985827A1 (en) 2015-05-14 2016-11-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112017024928A2 (pt) 2015-05-21 2018-07-31 Yeda Research And Development Co Ltd Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
US20180153944A1 (en) 2015-06-09 2018-06-07 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
WO2016209806A1 (en) 2015-06-22 2016-12-29 President And Fellows Of Harvard College Induction of lamina propria regulatory t cells
JP2018524354A (ja) 2015-07-08 2018-08-30 セレス セラピューティクス インコーポレイテッド 大腸炎を処置する方法
CN108289917A (zh) 2015-08-24 2018-07-17 努比约塔有限公司 使用粪源细菌群落来治疗微生态失衡的系统和方法
BR112018008358A2 (pt) 2015-10-26 2019-04-24 Crestovo Holdings Llc ?composições e métodos para terapia relacionada à microbiota fecal?
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US20190247447A1 (en) 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
WO2018005606A1 (en) * 2016-06-28 2018-01-04 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
JP2021524476A (ja) 2018-05-24 2021-09-13 セレス セラピューティクス インコーポレイテッド 設計された細菌組成物及びその使用
WO2020037271A1 (en) 2018-08-17 2020-02-20 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2022159711A1 (en) 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269321A1 (en) * 2005-03-03 2009-10-29 Toshihiro Sashihara Immune Function Modulating Agents
WO2011033310A1 (en) * 2009-09-17 2011-03-24 William John Martin Encapsulated intestinal flora extracted from feces for use in the treatment of gastrointestinal disorders
US20180221286A1 (en) * 2013-03-14 2018-08-09 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US20180169153A1 (en) * 2014-11-25 2018-06-21 Evelo Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft verses host disease
WO2017218680A1 (en) * 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180169157A1 (en) * 2016-06-14 2018-06-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
WO2018080477A1 (en) * 2016-10-26 2018-05-03 The Joan & Irwin Jacobs Technion-Cornell Institute Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHILIPP SOLBACH等: "BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection", PLOS ONE., vol. 13, no. 5, 8 May 2018 (2018-05-08), pages 1 - 20 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113486954A (zh) * 2021-07-06 2021-10-08 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
CN114496279A (zh) * 2022-01-12 2022-05-13 广州保量医疗科技有限公司 菌群移植配型的排序方法、系统、计算机设备及存储介质
CN119970806A (zh) * 2025-02-25 2025-05-13 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用
CN120779034A (zh) * 2025-07-15 2025-10-14 中山大学附属口腔医院 一种牙周炎相关标志物及应用

Also Published As

Publication number Publication date
JP7558170B2 (ja) 2024-09-30
IL280779B2 (en) 2025-05-01
JP2024119856A (ja) 2024-09-03
AU2019321681A1 (en) 2021-02-25
EP3836946A4 (en) 2022-05-04
JP2022500489A (ja) 2022-01-04
WO2020037271A1 (en) 2020-02-20
KR20210091119A (ko) 2021-07-21
EP3836946A1 (en) 2021-06-23
IL317775A (en) 2025-02-01
IL280779B1 (en) 2025-01-01
EP3836946B1 (en) 2026-04-22
US20250161375A1 (en) 2025-05-22
US20220143108A1 (en) 2022-05-12
IL280779A (en) 2021-04-29
US12161680B2 (en) 2024-12-10

Similar Documents

Publication Publication Date Title
US20250161375A1 (en) Methods of decreasing dysbiosis and restoring a microbiome
US11666612B2 (en) Network-based microbial compositions and methods
US11389490B2 (en) Synergistic bacterial compositions and methods of production and use thereof
US20250064869A1 (en) Synergistic bacterial compositions and methods of production and use thereof
JP6908332B2 (ja) 病原性細菌生育の抑制のための組成物および方法
JP6833514B2 (ja) 相乗作用のある細菌組成物ならびにその製造及び使用方法
JP2016519664A5 (https=)
US20230158088A1 (en) Compositions for modulating gut microflora populations, enhancing drug potency and treating viral infections, and methods for making and using same
KR20200138333A (ko) 염증성 장 질환을 치료하는 조성물 및 방법
KR20250155052A (ko) 장내 미생물총 개체군 조절, 장내 미생물 불균형의 치료 및 질환 예방을 위한 조성물, 및 이의 제조 및 사용 방법
US20240173365A1 (en) Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease
JP7851353B2 (ja) 腸内毒素症を減少させ、微生物叢を復元する方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination